Abstract
In the brain after infarction or trauma, the tissue becomes pannecrotic and forms a cavity. In such situation, a scaffold is necessary to produce new tissue. In this study, we implanted a new porous gelatin-siloxane hybrid derived from gelatin and 3-(glycidoxypropyl) trimethoxysilane (gelatin-GPTMS) scaffolds into a brain defect, and investigated whether it makes a new brain tissue. In addition, vascular endothelial growth factor (VEGF) was added on gelatin- GPTMS scaffolds and its effect on tissue regeneration was examined. At 30 days after the implantation, the marginal territory of the scaffolds became occupied by newly formed tissue. Immunohistochemical analysis revealed that the new tissue was constituted by endothelial, astroglial and microglial cells, some of which were labeled for bromodeoxyuridine (BrdU). Addition of VEGF promoted numbers of these cells. Thus, combination of gelatin-GPTMS scaffolds and VEGF is preferable for brain regeneration.
Keywords: Brain, scaffold, tissue regeneration, vascular endothelial growth factor
Current Neurovascular Research
Title: Gelatin-Siloxane Hybrid Scaffolds with Vascular Endothelial Growth Factor Induces Brain Tissue Regeneration
Volume: 5 Issue: 2
Author(s): Hanzhe Zhang, Tatsushi Kamiya, Takeshi Hayashi, Kanji Tsuru, Kentaro Deguchi, Violeta Lukic, Atsushi Tsuchiya, Toru Yamashita, Satoshi Hayakawa, Yoshio Ikeda, Akiyoshi Osaka and Koji Abe
Affiliation:
Keywords: Brain, scaffold, tissue regeneration, vascular endothelial growth factor
Abstract: In the brain after infarction or trauma, the tissue becomes pannecrotic and forms a cavity. In such situation, a scaffold is necessary to produce new tissue. In this study, we implanted a new porous gelatin-siloxane hybrid derived from gelatin and 3-(glycidoxypropyl) trimethoxysilane (gelatin-GPTMS) scaffolds into a brain defect, and investigated whether it makes a new brain tissue. In addition, vascular endothelial growth factor (VEGF) was added on gelatin- GPTMS scaffolds and its effect on tissue regeneration was examined. At 30 days after the implantation, the marginal territory of the scaffolds became occupied by newly formed tissue. Immunohistochemical analysis revealed that the new tissue was constituted by endothelial, astroglial and microglial cells, some of which were labeled for bromodeoxyuridine (BrdU). Addition of VEGF promoted numbers of these cells. Thus, combination of gelatin-GPTMS scaffolds and VEGF is preferable for brain regeneration.
Export Options
About this article
Cite this article as:
Zhang Hanzhe, Kamiya Tatsushi, Hayashi Takeshi, Tsuru Kanji, Deguchi Kentaro, Lukic Violeta, Tsuchiya Atsushi, Yamashita Toru, Hayakawa Satoshi, Ikeda Yoshio, Osaka Akiyoshi and Abe Koji, Gelatin-Siloxane Hybrid Scaffolds with Vascular Endothelial Growth Factor Induces Brain Tissue Regeneration, Current Neurovascular Research 2008; 5 (2) . https://dx.doi.org/10.2174/156720208784310204
DOI https://dx.doi.org/10.2174/156720208784310204 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on α7 nAChRs
Current Neuropharmacology Psychoemotional Background of Temporomandibular Joint Dysfunction and Possible Drug Therapy
Letters in Drug Design & Discovery Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research The Use of Bifunctional NOP/Mu and NOP Receptor Selective Compounds for the Treatment of Pain, Drug Abuse, and Psychiatric Disorders
Current Pharmaceutical Design The Development of Stem Cell-Based Treatment for Liver Failure
Current Stem Cell Research & Therapy Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry Central Nervous System-Related
Current Bioactive Compounds Cytochrome P450 in Neurological Disease
Current Drug Metabolism Calcium Channel α2δ Subunits: Structure, Functions and Target Site for Drugs
Current Neuropharmacology The Decisive Role of Mutual Arrangement of Hydroxy and Methoxy Groups in (3(4)-hydroxy-4(3)-methoxyphenyl)-4,7-dimethyl-3,4,4a,5,8,8ahexahydro- 2H-chromene-4,8-diols in their Biological Activity
Letters in Drug Design & Discovery Mesenchymal Stem Cells: Use in Cartilage Repair
Current Rheumatology Reviews Editorial (Thematic Issue: Natural and Synthetic Polyphenols as Emerging Drugs: Design, Delivery Systems and Preclinical & Clinical Therapeutic Approaches)
Current Drug Targets Plasticity and Therapeutic Potential of Mesenchymal Stem Cells in the Nervous System
Current Pharmaceutical Design Recent Advances on the Possible Neuroprotective Activities of Epstein- Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System
Current Neuropharmacology Drug Therapy in Brugada Syndrome
Current Drug Targets - Cardiovascular & Hematological Disorders Lipidomics as Tools for Finding Biomarkers of Intestinal Pathology: From Irritable Bowel Syndrome to Colorectal Cancer
Current Drug Targets Stem Cells and ßλατημa Cells
Current Stem Cell Research & Therapy Development of Multifunctional Nanoparticles for Targeted Drug Delivery and Noninvasive Imaging of Therapeutic Effect
Current Drug Discovery Technologies Triamcinolone Acetonide Inhibits p38MAPK Activation and Neuronal Apoptosis in Early Diabetic Retinopathy
Current Molecular Medicine Interaction Between Bone and Muscle in Older Persons with Mobility Limitations
Current Pharmaceutical Design